Palomino Labs Reports Equity Sales
| Field | Detail |
|---|---|
| Company | Palomino Laboratories Inc. |
| Form Type | 8-K |
| Filed Date | Oct 30, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $9,481,024, $1.50, $275,001.00, $1.80 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, unregistered-securities, 8-k
TL;DR
Palomino Labs sold unregistered equity on 10/24. Watch for dilution.
AI Summary
Palomino Laboratories Inc. filed an 8-K on October 30, 2025, reporting unregistered sales of equity securities that occurred on October 24, 2025. The company, formerly known as Unite Acquisition 3 Corp., is incorporated in Delaware and headquartered in Palo Alto, California.
Why It Matters
This filing indicates Palomino Laboratories Inc. has engaged in unregistered equity sales, which could impact share dilution and investor ownership structures.
Risk Assessment
Risk Level: medium — Unregistered equity sales can signal financial distress or dilutionary financing, requiring further investigation into the terms and impact.
Key Players & Entities
- Palomino Laboratories Inc. (company) — Registrant
- Unite Acquisition 3 Corp. (company) — Former company name
- October 24, 2025 (date) — Date of unregistered equity sales
- October 30, 2025 (date) — Filing date of the 8-K
- Delaware (jurisdiction) — State of incorporation
- Palo Alto, CA (location) — Principal executive offices
FAQ
What type of equity securities were sold?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the type of securities in the provided text.
What was the total dollar amount of the unregistered equity sales?
The specific dollar amount of the unregistered equity sales is not detailed in the provided excerpt of the 8-K filing.
Were these sales to accredited investors?
The filing mentions 'Unregistered Sales of Equity Securities,' which typically implies sales made under exemptions from registration, often to accredited investors, but this is not explicitly stated in the provided text.
What is the reason for these unregistered equity sales?
The provided text of the 8-K filing does not disclose the specific reasons behind the unregistered sales of equity securities.
When did Palomino Laboratories Inc. change its name from Unite Acquisition 3 Corp.?
The filing indicates the date of the name change from Unite Acquisition 3 Corp. to Palomino Laboratories Inc. was July 19, 2022.
Filing Stats: 755 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2025-10-30 16:18:26
Key Financial Figures
- $9,481,024 — ts") for an aggregate purchase price of $9,481,024.50, with a purchase price of $1.50 per
- $1.50 — $9,481,024.50, with a purchase price of $1.50 per Unit. Each Unit consists of (i) one
- $275,001.00 — to 183,334 Units for gross proceeds of $275,001.00 (the "Offering"). The offering and sale
- $1.80 — gent Warrants have an exercise price of $1.80 per share and a term of seven (7) years
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex4-1.htm (EX-4.1) — 113KB
- ex4-2.htm (EX-4.2) — 121KB
- ex10-9.htm (EX-10.9) — 389KB
- 0001493152-25-020229.txt ( ) — 955KB
- uniteacq3-20251024.xsd (EX-101.SCH) — 3KB
- uniteacq3-20251024_lab.xml (EX-101.LAB) — 33KB
- uniteacq3-20251024_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 4.1 Form of Subscription Agreement 4.2 Form of Warrant 10.9 Form of Placement Agent Warrant 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2025 PALOMINO LABORATORIES INC. By: /s/ Jeffrey B. Shealy Name: Jeffrey B. Shealy Title: Chief Executive Officer